HitGen(SH:688222)2024-10-17 09:44Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. aims to become a world-class innovative biopharmaceutical company focused on improving human health [3][4] - The company specializes in the discovery and optimization of small molecules and nucleic acid drugs, leveraging advanced technologies such as DNA-encoded compound libraries (DEL) [3][4] Key Technologies - The DEL library has surpassed 1.2 trillion molecules, making it the largest known small molecule compound library globally [4][6] - The company has designed and synthesized over 6,000 types of molecular scaffolds, covering most core scaffolds of currently approved small molecule drugs and many advantageous scaffolds of clinical projects [6][8] - The company has developed nearly 170 types of chemical reactions for DEL synthesis, enhancing the efficiency of drug discovery [6][7] Business Model - Chengdu XianDao employs a diversified business model, providing innovative drug solutions to meet unmet clinical needs globally [4][10] - The DEL alliance, formed with major pharmaceutical companies, aims to share resources and accelerate drug discovery and development [10][11] Financial Performance - The gross margin of the UK subsidiary is around 20%, which is lower than several other business segments [11][12] - The company is actively working to enhance collaboration between domestic and international teams to improve project success rates and overall profitability [12] Future Prospects - The integration of DEL technology with AI and high-throughput DMTA platforms is expected to enhance the efficiency of drug discovery processes [13][15] - The company aims to provide innovative, rapid, and reliable solutions for clinical candidates targeting difficult-to-drug targets [15]